Emodin down-regulates ERCC1 and Rad51 and inhibits proliferation in non-small cell lung cancer cells

He Lin; Bi Juanjuan; Guo Qian; Yu Yin; Ye Xiufeng; Li Wei

您当前的位置：

首页 >

文章列表页 >

Emodin down-regulates ERCC1 and Rad51 and inhibits proliferation in non-small cell lung cancer cells

更新时间：2025-01-15

- Emodin down-regulates ERCC1 and Rad51 and inhibits proliferation in non-small cell lung cancer cells
- Journal of Army Medical University Vol. 33, Issue 22, Pages: 2370-2375(2011)
- 作者机构：
  
  重庆医科大学基础医学院病理学教研室，重庆市神经生物学重点实验室
- 作者简介：
- 基金信息：
- DOI：
  CLC： R734.2;R285.5;R730.23
- Published：2011，
  
  Published Online：30 November 2011，
- 稿件说明：
移动端阅览
HE LIN, BI JUANJUAN, GUO QIAN, et al. Emodin down-regulates ERCC1 and Rad51 and inhibits proliferation in non-small cell lung cancer cells. [J]. Journal of army medical university, 2011, 33(22): 2370-2375.
DOI：

HE LIN, BI JUANJUAN, GUO QIAN, et al. Emodin down-regulates ERCC1 and Rad51 and inhibits proliferation in non-small cell lung cancer cells. [J]. Journal of army medical university, 2011, 33(22): 2370-2375. DOI：

摘要

目的研究大黄素对非小细胞肺癌的细胞毒性，并观察其对非小细胞肺癌ERCC1和Rad51表达的影响。方法培养肺腺癌细胞株A549和肺鳞癌细胞株SK-MES-1，据MTT法测定结果将细胞分为5组：①对照组；②大黄素处理组；③溶剂处理组；④U0126处理组；⑤大黄素联合U0126处理组。细胞以不同浓度的大黄素处理48 h后分为4组。用RT-PCR和Western blot法测定目的基因RECC1和Rad51的表达情况，透射电镜观察两种细胞在大黄素作用前后的变化。结果 MTT法测定出大黄素作用48 h时A549和 SK-MES-1细胞株IC

值分别为（70.18±1.94）μmol/L和（41.95±1.27）μmol/L。大黄素100 μmol/L处理A549和SK-MES-1 48 h后抑制率为（60.42±1.37）%和（75.48±0.48）%，明显高于其他组（

0.05）。RT-PCR和Western blot检测结果显示：大黄素作用A549和SK-MES-1浓度越大，ERCC1和Rad51表达水平越低，且差异具有统计学意义（

0.05）。大黄素与ERK信号通路阻滞剂U0126联合使用时，ERCC1和Rad51表达明显低于大黄素和U0126单独使用（

0.05）。大黄素对A549和SK-MES-1细胞均具有生长抑制作用，其细胞毒性呈浓度依赖性。电镜观察可见大黄素处理的A549和SK-MES-1细胞有空泡变性。结论大黄素可降低ERCC1和Rad51的表达，从而引起非小细胞肺癌细胞生长抑制。

Abstract

Objective To study emodin-mediated cytotoxicity and determine the effect of emodin on Rad51 and ERCC1 expression in non-small cell lung cancer (NSCLC). Methods A549 cells and SK-MES-1 cells were cultured and their viability was evaluated by 3-(4

5-dimethylthiazol-2-yl)-2

5-diphenyltet

razolium bromide (MTT) assay. Then the cells were treated by emodin

menstruum

U0126 (ERK signal passway inhibitor)

or emodin+U0126 respectively. After the cells were treated with emodin at different concentrations for 48 h

the mRNA and protein levels of ERCC1 and Rad51 were determined by RT-PCR and Western blot analysis. The ultrastructure of A549 and SK-MES-1 cells were observed by transmission electron microscopy before and after emodin treatment. Results After emodin treatment for 48 h

MTT assay showed that the IC

values of A549 cells and SK-MES-1 cells were 70.18±1.94 and 41.95±1.27 μmol/L

respectively. Cell proliferation inhibition ratio in A549 and SK-MES-1 cells were (60.42±1.37)% and (75.48±0.48)% after 100 μmol/L emodin treatment for 48 h

respectively

and were significantly higher than those in cells after other treatment (

0.05). RT-PCR and Western blot analysis showed that emodin inhibited the mRNA and protein levels of ERCC1 and Rad51 in A549 and SK-MES-1 cells in a dose dependent manner (

0.05). The combination of emodin and U0126 had a stronger effect on inhibiting the expressions of Rad51 and ERCC1 when compared with single drug at the same dose (

0.05). Emodin mediated cytotoxicity in NSCLC was in a dose dependent manner. Transmission electron microscopy displayed vacuolar degenerations were observed in A549 and SK-MES-1 cells after emodin treatment. Conclusion Emodin inhibits cell proliferation in NSCLC by downregulating ERCC1 and Rad51.

关键词

大黄素ERCC1Rad51U0126空泡变性

Keywords

emodinERCC1Rad51U0126vacuolar degeneration

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of emodin on proliferation and intracellular free calcium of hypertrophic scar fibroblasts in vitro

Effect of ERK pathway inhibitor U0126 on cell cycle of leukemia K562 cell lines

Emodin induces apoptosis and down-regulates Bcl-2/Bax in leukemia KG-1a cells

Related Author

LIU Jingyi

CAI Lun

DUAN Hao

LIU Chang

LI Haibo

LIU Ming

Zhang Yan

Zhang Yaolei

Related Institution

Department of Microbiology and Biochemical Pharmacy, National Engineering Technology Research Center for Immunobiological Products, 2Department of Analytical Chemistry, Faculty of Pharmacy and Medical Laboratory, Army Medical University (Third Military Medical University)

Clinical School of Medicine, Jiamusi University

Central Laboratory, Department of Cardiology, Department of General Surgery, General Hospital of Chengdu Military Command

Department of Plastic Surgery, Southwest Hospital, Third Millitary Medical University

Department of Hematology, the Second Hospital of Hebei Medical University

⁰